- Home
- CGEN vs RSSS Comparison
CGEN vs RSSS Comparison
Compare CGEN & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- RSSS
- Stock Information
- Founded
- CGEN 1993
- RSSS 2006
- Country
- CGEN Israel
- RSSS United States
- Employees
- CGEN N/A
- RSSS N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- RSSS Business Services
- Sector
- CGEN Health Care
- RSSS Consumer Discretionary
- Exchange
- CGEN Nasdaq
- RSSS Nasdaq
- Market Cap
- CGEN 142.4M
- RSSS 131.6M
- IPO Year
- CGEN 2000
- RSSS N/A
- Fundamental
- Price
- CGEN $2.25
- RSSS $3.65
- Analyst Decision
- CGEN Strong Buy
- RSSS Strong Buy
- Analyst Count
- CGEN 1
- RSSS 1
- Target Price
- CGEN $4.00
- RSSS $6.00
- AVG Volume (30 Days)
- CGEN 898.9K
- RSSS 169.0K
- Earning Date
- CGEN 03-04-2025
- RSSS 02-06-2025
- Dividend Yield
- CGEN N/A
- RSSS N/A
- EPS Growth
- CGEN N/A
- RSSS N/A
- EPS
- CGEN 0.02
- RSSS N/A
- Revenue
- CGEN $59,852,000.00
- RSSS $46,607,410.00
- Revenue This Year
- CGEN $57.27
- RSSS $13.30
- Revenue Next Year
- CGEN N/A
- RSSS $8.35
- P/E Ratio
- CGEN $125.59
- RSSS N/A
- Revenue Growth
- CGEN 698.03
- RSSS 19.26
- 52 Week Low
- CGEN $1.35
- RSSS $2.38
- 52 Week High
- CGEN $3.03
- RSSS $4.24
- Technical
- Relative Strength Index (RSI)
- CGEN 81.70
- RSSS 42.52
- Support Level
- CGEN $1.92
- RSSS $3.69
- Resistance Level
- CGEN $2.16
- RSSS $4.00
- Average True Range (ATR)
- CGEN 0.15
- RSSS 0.19
- MACD
- CGEN 0.07
- RSSS -0.07
- Stochastic Oscillator
- CGEN 88.90
- RSSS -1.72
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.